Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma

Neil S. Patel, Michael J. Link, Colin L.W. Driscoll, Bruce E. Pollock, Christine M. Lohse, Matthew L. Carlson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To describe audiometric outcomes following stereotactic radiosurgery (SRS) for jugular paraganglioma (JP). Study Design: Retrospective review. Setting: Tertiary referral center. Patients: Patients with pretreatment serviceable hearing (American Academy of Otolaryngology - Head and Neck Surgery [AAO-HNS] Class A or B) and serial post-SRS audiometric follow-up who underwent Gamma Knife SRS for JP between 1990 and 2017. Intervention(s): Gamma Knife SRS. Main Outcome Measures: Progression to nonserviceable hearing; correlation between baseline hearing and treatment parameters with audiometric outcomes. Results: Of 85 patients with JP who underwent SRS during the study period, 35 (66% female, median age 53) had pretreatment serviceable hearing and serial post-treatment audiometry available for review. Median tumor volume at the time of treatment was 7,080 mm 3, median cochlear point dose was 5.8 Gy (interquartile range [IQR] 4.1 to 7.3 Gy), and median marginal and maximum tumor doses were 16 and 32 Gy, respectively. After a median follow-up of 37 months (IQR 16 to 77 mo), the median change in pure-tone average and speech discrimination score in the treated ear was -1.2 dB HL/yr (IQR -4.5 to 0.3) and 0%/yr (IQR 0-3.5%), compared with 0.07 dB HL/yr (IQR -0.03 to 0.12) and 0 %/yr (IQR 0 to 0%) in the contralateral untreated ear. Seven patients developed nonserviceable hearing (AAO-HNS Class C or D) at a median of 13.2 months following SRS (IQR 4.8 to 24 mo). Among those who maintained serviceable hearing, median audiometric follow-up was 42 months (IQR 18 to 77 mo). The Kaplan-Meier estimated rates of serviceable hearing at 1, 3, and 5 years following SRS were 91%, 80%, and 80%, respectively. Sixty percent of patients with pulsatile tinnitus who underwent SRS experienced varying levels of symptomatic improvement following treatment. Conclusion: The short- and intermediate-term risk of progression to nonserviceable hearing following SRS for JP is low. Data regarding the impact of cochlear dose from the vestibular schwannoma literature should not be freely applied to JP, since the impact of SRS parameters on hearing preservation seems to be less significant.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalOtology and Neurotology
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Paraganglioma
Radiosurgery
Hearing
Neck
Cochlea
Otolaryngology
Ear
Head
Audiometry
Speech Perception
Acoustic Neuroma
Tinnitus
Therapeutics
Tumor Burden
Tertiary Care Centers
Retrospective Studies

Keywords

  • Conductive hearing loss
  • Gamma knife
  • Glomus jugulare
  • Paraganglioma
  • Sensorineural hearing loss
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Sensory Systems
  • Clinical Neurology

Cite this

Patel, N. S., Link, M. J., Driscoll, C. L. W., Pollock, B. E., Lohse, C. M., & Carlson, M. L. (2018). Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma. Otology and Neurotology, 39(1), 99-105. https://doi.org/10.1097/MAO.0000000000001636

Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma. / Patel, Neil S.; Link, Michael J.; Driscoll, Colin L.W.; Pollock, Bruce E.; Lohse, Christine M.; Carlson, Matthew L.

In: Otology and Neurotology, Vol. 39, No. 1, 01.01.2018, p. 99-105.

Research output: Contribution to journalArticle

Patel, NS, Link, MJ, Driscoll, CLW, Pollock, BE, Lohse, CM & Carlson, ML 2018, 'Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma', Otology and Neurotology, vol. 39, no. 1, pp. 99-105. https://doi.org/10.1097/MAO.0000000000001636
Patel NS, Link MJ, Driscoll CLW, Pollock BE, Lohse CM, Carlson ML. Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma. Otology and Neurotology. 2018 Jan 1;39(1):99-105. https://doi.org/10.1097/MAO.0000000000001636
Patel, Neil S. ; Link, Michael J. ; Driscoll, Colin L.W. ; Pollock, Bruce E. ; Lohse, Christine M. ; Carlson, Matthew L. / Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma. In: Otology and Neurotology. 2018 ; Vol. 39, No. 1. pp. 99-105.
@article{726b75d103c54c50a1aca13620c26ffb,
title = "Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma",
abstract = "Objective: To describe audiometric outcomes following stereotactic radiosurgery (SRS) for jugular paraganglioma (JP). Study Design: Retrospective review. Setting: Tertiary referral center. Patients: Patients with pretreatment serviceable hearing (American Academy of Otolaryngology - Head and Neck Surgery [AAO-HNS] Class A or B) and serial post-SRS audiometric follow-up who underwent Gamma Knife SRS for JP between 1990 and 2017. Intervention(s): Gamma Knife SRS. Main Outcome Measures: Progression to nonserviceable hearing; correlation between baseline hearing and treatment parameters with audiometric outcomes. Results: Of 85 patients with JP who underwent SRS during the study period, 35 (66{\%} female, median age 53) had pretreatment serviceable hearing and serial post-treatment audiometry available for review. Median tumor volume at the time of treatment was 7,080 mm 3, median cochlear point dose was 5.8 Gy (interquartile range [IQR] 4.1 to 7.3 Gy), and median marginal and maximum tumor doses were 16 and 32 Gy, respectively. After a median follow-up of 37 months (IQR 16 to 77 mo), the median change in pure-tone average and speech discrimination score in the treated ear was -1.2 dB HL/yr (IQR -4.5 to 0.3) and 0{\%}/yr (IQR 0-3.5{\%}), compared with 0.07 dB HL/yr (IQR -0.03 to 0.12) and 0 {\%}/yr (IQR 0 to 0{\%}) in the contralateral untreated ear. Seven patients developed nonserviceable hearing (AAO-HNS Class C or D) at a median of 13.2 months following SRS (IQR 4.8 to 24 mo). Among those who maintained serviceable hearing, median audiometric follow-up was 42 months (IQR 18 to 77 mo). The Kaplan-Meier estimated rates of serviceable hearing at 1, 3, and 5 years following SRS were 91{\%}, 80{\%}, and 80{\%}, respectively. Sixty percent of patients with pulsatile tinnitus who underwent SRS experienced varying levels of symptomatic improvement following treatment. Conclusion: The short- and intermediate-term risk of progression to nonserviceable hearing following SRS for JP is low. Data regarding the impact of cochlear dose from the vestibular schwannoma literature should not be freely applied to JP, since the impact of SRS parameters on hearing preservation seems to be less significant.",
keywords = "Conductive hearing loss, Gamma knife, Glomus jugulare, Paraganglioma, Sensorineural hearing loss, Stereotactic radiosurgery",
author = "Patel, {Neil S.} and Link, {Michael J.} and Driscoll, {Colin L.W.} and Pollock, {Bruce E.} and Lohse, {Christine M.} and Carlson, {Matthew L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MAO.0000000000001636",
language = "English (US)",
volume = "39",
pages = "99--105",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hearing Outcomes after Stereotactic Radiosurgery for Jugular Paraganglioma

AU - Patel, Neil S.

AU - Link, Michael J.

AU - Driscoll, Colin L.W.

AU - Pollock, Bruce E.

AU - Lohse, Christine M.

AU - Carlson, Matthew L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To describe audiometric outcomes following stereotactic radiosurgery (SRS) for jugular paraganglioma (JP). Study Design: Retrospective review. Setting: Tertiary referral center. Patients: Patients with pretreatment serviceable hearing (American Academy of Otolaryngology - Head and Neck Surgery [AAO-HNS] Class A or B) and serial post-SRS audiometric follow-up who underwent Gamma Knife SRS for JP between 1990 and 2017. Intervention(s): Gamma Knife SRS. Main Outcome Measures: Progression to nonserviceable hearing; correlation between baseline hearing and treatment parameters with audiometric outcomes. Results: Of 85 patients with JP who underwent SRS during the study period, 35 (66% female, median age 53) had pretreatment serviceable hearing and serial post-treatment audiometry available for review. Median tumor volume at the time of treatment was 7,080 mm 3, median cochlear point dose was 5.8 Gy (interquartile range [IQR] 4.1 to 7.3 Gy), and median marginal and maximum tumor doses were 16 and 32 Gy, respectively. After a median follow-up of 37 months (IQR 16 to 77 mo), the median change in pure-tone average and speech discrimination score in the treated ear was -1.2 dB HL/yr (IQR -4.5 to 0.3) and 0%/yr (IQR 0-3.5%), compared with 0.07 dB HL/yr (IQR -0.03 to 0.12) and 0 %/yr (IQR 0 to 0%) in the contralateral untreated ear. Seven patients developed nonserviceable hearing (AAO-HNS Class C or D) at a median of 13.2 months following SRS (IQR 4.8 to 24 mo). Among those who maintained serviceable hearing, median audiometric follow-up was 42 months (IQR 18 to 77 mo). The Kaplan-Meier estimated rates of serviceable hearing at 1, 3, and 5 years following SRS were 91%, 80%, and 80%, respectively. Sixty percent of patients with pulsatile tinnitus who underwent SRS experienced varying levels of symptomatic improvement following treatment. Conclusion: The short- and intermediate-term risk of progression to nonserviceable hearing following SRS for JP is low. Data regarding the impact of cochlear dose from the vestibular schwannoma literature should not be freely applied to JP, since the impact of SRS parameters on hearing preservation seems to be less significant.

AB - Objective: To describe audiometric outcomes following stereotactic radiosurgery (SRS) for jugular paraganglioma (JP). Study Design: Retrospective review. Setting: Tertiary referral center. Patients: Patients with pretreatment serviceable hearing (American Academy of Otolaryngology - Head and Neck Surgery [AAO-HNS] Class A or B) and serial post-SRS audiometric follow-up who underwent Gamma Knife SRS for JP between 1990 and 2017. Intervention(s): Gamma Knife SRS. Main Outcome Measures: Progression to nonserviceable hearing; correlation between baseline hearing and treatment parameters with audiometric outcomes. Results: Of 85 patients with JP who underwent SRS during the study period, 35 (66% female, median age 53) had pretreatment serviceable hearing and serial post-treatment audiometry available for review. Median tumor volume at the time of treatment was 7,080 mm 3, median cochlear point dose was 5.8 Gy (interquartile range [IQR] 4.1 to 7.3 Gy), and median marginal and maximum tumor doses were 16 and 32 Gy, respectively. After a median follow-up of 37 months (IQR 16 to 77 mo), the median change in pure-tone average and speech discrimination score in the treated ear was -1.2 dB HL/yr (IQR -4.5 to 0.3) and 0%/yr (IQR 0-3.5%), compared with 0.07 dB HL/yr (IQR -0.03 to 0.12) and 0 %/yr (IQR 0 to 0%) in the contralateral untreated ear. Seven patients developed nonserviceable hearing (AAO-HNS Class C or D) at a median of 13.2 months following SRS (IQR 4.8 to 24 mo). Among those who maintained serviceable hearing, median audiometric follow-up was 42 months (IQR 18 to 77 mo). The Kaplan-Meier estimated rates of serviceable hearing at 1, 3, and 5 years following SRS were 91%, 80%, and 80%, respectively. Sixty percent of patients with pulsatile tinnitus who underwent SRS experienced varying levels of symptomatic improvement following treatment. Conclusion: The short- and intermediate-term risk of progression to nonserviceable hearing following SRS for JP is low. Data regarding the impact of cochlear dose from the vestibular schwannoma literature should not be freely applied to JP, since the impact of SRS parameters on hearing preservation seems to be less significant.

KW - Conductive hearing loss

KW - Gamma knife

KW - Glomus jugulare

KW - Paraganglioma

KW - Sensorineural hearing loss

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85039435163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039435163&partnerID=8YFLogxK

U2 - 10.1097/MAO.0000000000001636

DO - 10.1097/MAO.0000000000001636

M3 - Article

C2 - 29194225

AN - SCOPUS:85039435163

VL - 39

SP - 99

EP - 105

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

IS - 1

ER -